Participants with Treatment-emergent Adverse Experiences Up to Day 169 [clinicaltrials_resource:27168a72006b7143b12910030cfb7638]
BSAP is a biomarker of bone formation.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Participants with Treatment-emergent Adverse Experiences Up to Day 169 [clinicaltrials_resource:27168a72006b7143b12910030cfb7638]
BSAP is a biomarker of bone formation.
Bio2RDF identifier
27168a72006b7143b12910030cfb7638
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:27168a72006b7143b12910030cfb7638
measure [clinicaltrials_vocabulary:measure]
Participants with Treatment-emergent Adverse Experiences
time frame [clinicaltrials_vocabulary:time-frame]
Up to Day 169
description
BSAP is a biomarker of bone formation.
identifier
clinicaltrials_resource:27168a72006b7143b12910030cfb7638
title
Participants with Treatment-emergent Adverse Experiences Up to Day 169
@en
type
label
Participants with Treatment-em ...... 68a72006b7143b12910030cfb7638]
@en